NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted ...

Core Insights - Psyence Biomedical Ltd. is the first publicly listed company to investigate the potential impact of psilocybin on longevity, collaborating with researchers in South Africa [1][6] - The initiative aims to explore psilocybin's effects on biological markers associated with aging, which could redefine human longevity and transform aging [1][6] Industry Context - Longevity science is gaining global attention due to aging populations and rising healthcare costs, with public figures like Bryan Johnson promoting psychedelic therapies for longevity [2][6] - Scientific literature supports the intersection of psychedelics and aging biology, with preclinical research indicating that psilocin can extend survival in aged mouse models and increase the lifespan of human cells by over 50% [2] Research Initiative - Psyence BioMed is developing a preclinical protocol to evaluate psilocybin's influence on biological mechanisms related to aging, focusing on biomarkers of cellular stress, inflammation, and mitochondrial function [3] - The research will be led by Dr. Tanya Calvey, a recognized neuroscientist specializing in neuropsychopharmacology, to rigorously investigate the effects of psilocybin on aging [4][5] Strategic Positioning - The initiative complements Psyence BioMed's existing clinical programs, including psilocybin-assisted therapy trials for palliative care patients, advancing the company's mission to explore the therapeutic potential of psilocybin and ibogaine [7] - The company is positioned at the forefront of a new therapeutic arena, with significant interest in understanding how psilocybin may influence biological aging [6]

Core Viewpoint - Psyence Biomedical Ltd. has established a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, which is crucial for the clinical development of ibogaine for substance use disorders [1][2][4] Group 1: Supply Chain and Product Development - The collaboration with PsyLabs ensures a long-term supply of GMP-compliant ibogaine, with the first 50 kg received and being processed into pharmaceutical-grade ibogaine HCL and Total Alkaloid Extracts [2][3] - The company is committed to ethical sourcing and sustainability, ensuring that ibogaine and related alkaloids are derived from Tabernanthe iboga and Voacanga africana while respecting cultural traditions and benefiting source communities [3][4] Group 2: Strategic Positioning and Market Leadership - The establishment of a reliable and ethically sourced supply chain positions Psyence BioMed as a leader in the emerging ibogaine sector, enhancing its competitive advantage as international interest in ibogaine grows [4] - The company aims to set a new standard for ethical psychedelic production, emphasizing partnerships with traditional knowledge holders rather than treating them merely as suppliers [4][6] Group 3: Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine, addressing unmet mental health needs [6] - The company is the first life sciences biotechnology firm specializing in psychedelic therapeutics to be listed on Nasdaq, reflecting its commitment to an evidence-based approach in developing safe and effective treatments [6]

Core Viewpoint - Psyence BioMed is positioned as the only publicly listed psychedelics company with active operations and manufacturing capabilities in Africa, enhancing its access to ibogaine, a compound derived from the Tabernanthe iboga shrub, which is crucial for developing therapies for mental health needs [1][2]. Company Overview - Psyence BioMed focuses on nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, particularly in palliative care [10]. - The company has established a strategic investment in PsyLabs, which operates a GMP-compliant facility in Southern Africa, producing highly purified psychedelic compounds [3][9]. Strategic Positioning - By operating at the source of ibogaine, Psyence BioMed can ensure sustainable and responsible access to this compound, allowing for quality control from cultivation to finished product [2][3]. - The vertical integration of Psyence BioMed's operations strengthens supply security and scalability, positioning the company favorably within the psychedelics sector [3][8]. Market Trends - There is a global surge in interest and research surrounding ibogaine as a potential treatment for addiction and mental health disorders, with significant findings indicating its effectiveness in reducing PTSD symptoms among veterans [4][5]. - The State of Texas has allocated $50 million for clinical research on ibogaine, aiming to develop FDA-approved treatments for opioid use disorder, which reflects growing governmental support for psychedelic medicine [5]. Industry Developments - Major pharmaceutical companies, such as AbbVie, are increasingly investing in psychedelic compounds, highlighting the clinical potential of ibogaine and its analogs [6][7]. - Psyence BioMed is actively engaged in developing next-generation analogs of ibogaine, aligning with the industry's shift towards innovative therapeutic solutions [6][8]. Supply Chain and Compliance - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, ensuring compliance with safety and traceability standards [9][10]. - The company's operations are supported by an ISO 22000-certified facility, emphasizing its commitment to high safety standards and regulatory compliance [10].

Psychedelics & Longevity - The report highlights potential interest in psilocybin for longevity purposes [1] - Suggests a dosage of 5 grams of psilocybin for experimentation [1] Social Media Activity - The content originates from a tweet by @miragemunny [1] - The tweet references a conversation involving "bryan" and his team [1]

Core Insights - Psyence Biomedical Ltd. has made a follow-on investment of USD 3,500,000 in PsyLabs, enhancing its supply chain for psychedelic compounds [1][2] - This investment follows a previous investment of USD 500,000 in April 2025, indicating a strong commitment to securing high-quality, GMP-grade psychedelic ingredients [2][3] - The CEO of Psyence BioMed emphasized the strategic importance of this investment in building a fully integrated company focused on sustainable and scalable production [3] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in nature-derived psilocybin and ibogaine therapies aimed at addressing unmet mental health needs [7] - It is the first life sciences biotechnology company focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq [7] - The company aims to create safe, effective, and FDA-approved treatments for a range of mental health disorders [7] Partnership and Production - PsyLabs is recognized as a leading producer of purified psychedelic active pharmaceutical ingredients (APIs) and is federally licensed to cultivate and export various psychedelic compounds [9] - The partnership between Psyence BioMed and PsyLabs is strengthened through this investment, positioning Psyence as a leader in the emerging psychedelic therapeutics sector [5] - PsyLabs operates a state-of-the-art facility in Southern Africa, utilizing the region's botanical heritage under strict ethical and sustainable practices [4][10] Strategic Goals - The investment aims to secure a reliable supply of premium psychedelic compounds for Psyence BioMed's clinical research programs, ensuring long-term value for investors [2][3] - The company is focused on building a responsible global supply chain, which is crucial for advancing its clinical pipeline and commercial opportunities [3][5]

Research Focus - The study explores how religious clergy experience and interpret the effects of psilocybin, the active ingredient in magic mushrooms [1] Experimental Design - An experimental study investigated the effects of psilocybin on religious clergy [1]

Core Viewpoint - Red Light Holland has successfully shipped its naturally occurring psilocybin from its Netherlands facility to Irvine Labs in California, marking a significant milestone in their partnership and advancing their goal of developing microdosing capsules for global distribution [2][4][5]. Group 1: Shipment and Partnership - The shipment of psilocybin was made possible through the approval of a United States Controlled Substances import permit and the securing of a DEA quota [2][3]. - This first global shipment represents a groundbreaking milestone in the collaboration between Red Light Holland and Irvine Labs, with potency testing and shelf life extension protocols currently underway [3][5]. Group 2: Product Development and Research - The partnership aims to develop a commercialized and standardized psilocybin product that can be legally sold in emerging markets and utilized in government-funded pilot programs and clinical trials in the United States [5]. - Red Light Holland is focused on overcoming challenges in product development and manufacturing by implementing proprietary preservation technology to maintain the integrity of natural compounds while extending product shelf life [6]. Group 3: Future Plans and Capacity - Irvine Labs has the capacity for larger shipments under its existing 2025 DEA quota, allowing for the scaling of research and development efforts following the initial shipment [7]. - The companies plan to conduct comprehensive potency testing and shelf life extension testing of the delivered psilocybin materials, with future larger shipments already being planned [11].

Psychedelic Medicine - Psychedelic medicine 行业关注 psilocybin（一种迷幻蘑菇中的活性成分）的潜力，这得益于最近的一项研究 [1] - Ibogaine（一种从非洲灌木 Iboga 中提取的物质）也被 Psychedelic medicine 行业关注，因为各州正在努力批准相关药物 [1]